Global Antibody Production Market

Antibody Production Market Insight

The process of antibody production involves the process of developing certain antibodies that require the use of immunization, hybridoma production, immunogen preparation, purification, and screening. The antibody production domain has experienced technological expansion since 1975. The development of hybridoma technology for antibody production is widely used. The use of hybridoma technology helps in the production of monoclonal antibodies.

The production of the antibodies is critical from clinical medicine and biological research point of view. Clinical research’s importance in developing diagnosis and medical devices is rapidly growing as the world faces an increasing burden of lifestyle concerning diseases and the spread of the novel COVID-19. 

The rise in the lifestyle concerning diseases like cancer also has the potential use of monoclonal antibodies (mAb). These antibodies equip the body’s immune system to combat cancer. The use of the mAb therapy has also been rendered effective in the treatment of COVID-19 patients and such therapy has also received FDA approvals to better serve public health. In November 2020, the FDA approved and authorized the use of mAb therapy to reduce the burden on the healthcare system. In 2017 also, various monoclonal antibodies were cleared and approved for therapeutic use by the FDA and EMA. The therapeutic indications included asthma, multiple sclerosis, and hemorrhage among others.

As the market moves in the direction of advanced technology, software tools are becoming important in solving the complex structure of the antibodies. Software tools like the PEAKS AB have been deployed to understand the characteristics of the monoclonal antibodies.

The monoclonal antibodies are classified as the main driver of the biotech industry and also lead the market for therapeutic drugs. The growing investment in monoclonal antibodies will create a huge market investment pool for the anti production market in general. In 2012, the mAb drugs were the top demanded drugs in the USA, and recorded revenue in billion dollars.

The market is also benefitted from the investment secured by the startups operating in the biopharmaceutical space.  Firms such as Mabwell Biotech raised RMB 1.97 Million to expand their production of biopharma products.

The antibody-based immunotherapy startups are also being glorified as equipping immunotherapy with antibody therapy which can deliver substantial results for successful cancer treatment. Thus higher investment in these startups and companies can also lead to the development of advanced therapies to cater to cancer patients. Alexion, Forty-Seven, and Harbour BioMed are a few of the startups in this space. Harbour Biomed in July 2020 raised over US$300 million to support the advancement of the preclinical molecules.

The market’s growth is also highly influenced by the summits presented by the manufactures investing in the biologics and production capacities to expand the biologics domain. WuXi Apptec in the year 2012 inaugurated the monoclonal antibody seminar on a global scale.

The manufacturers of the antibodies are participating in the rigorous launch of the antibodies to treat diseases like plaque psoriasis. Companies like Takeda Pharmaceutical are developing plasma-derived antibodies for COVID-19 treatment taking a different route from the laboratory-made antibody.

The expansion of the market is also reliable on the new manufacturing facilities dedicated to antibody production. Nippon Kayaku and Mitsubishi Gas Chemical in 2016 announced to start the production of mAb drugs in Niigata.

Europe’s leading startups are also revolutionizing the antibody production domain to develop novel therapies and treatments. Pluvia, FerroSens, and Adcendo are a few of the startups developing therapeutics antibodies. Yurogen Biosystems–USA-based startup is manufacturing humanized mAbs. Startups are rapidly developing technology platforms and space to handle the COVID-19 situation better. Tychan another startup is using convergence analytics to fasten the biologics process for the human trial.

The marketing of the monoclonal antibodies is also leading to high market demand as it brings in fresh investment and allows manufacturers to merge and alliance.

Other technologies that have shaped the market structure have been the presence of the technologies like the SMARt-Ig and ARt-Ig. The participation of the academic institutes and the use of research networks enhance the drug discovery process.

Antibody Production Market: By Process

Downstream processing would be occupying a major space owing to its wide importance in the biotech sector. The downstream processing plays a key role in removing impurities from the antibodies and also helps in stabilizing the product. These processing systems also serve as the cost-efficient method to simplify and purify the whole mAb processes.

Antibody Production Market: By End User

Pharmaceutical and Biotechnology companies would have high-interest stakes in antibody production. Antibodies are serving as the main revenue generation source of the pharmaceutical industry in comparison to small molecules. The innovation in the monoclonal antibodies and positive approval rate of the mAb drugs by regulatory authorities would have a positive bearing on the pharmaceutical industry. The dynamic field of monoclonal therapeutics and its rapidly rising market will have a positive impact on the segment’s growth.

Diagnostic laboratories would be the second-largest user of the antibodies owing to the efficacy and safety provided by the clinical labs in the monitoring of the antibodies’ drugs. Diagnosis is important in the management of the risk associated with the treatment using mAbs.

Antibody Production Market: By Region

North America’s dominant position is the result of the regulatory body’s important role in the approval of the antibodies and the rising market for mAb drugs and therapeutics for certain diseases in the region. The rise in the drug approval and biotech field would also have a positive impact on the region’s market growth.

Asia Pacific’s rising growth would be supported by the trending mergers between the companies to develop the novel mAb and also the untapped potential of the countries like India in the antibody production domain. Countries such as China are also developing monoclonal antibodies at a rapid rate to better fight the COVID-19.

Market Share and Competitive Analysis

Serum Institute, Sun Pharma, Sumit Biosciences, Biogeniux, Merck KGaA, GE Healthcare, Abcam Plc, Sino Biological, Genscript,  Nippon Kayaku,  and Chugai are key players functioning in this market.

 Please note: This is not an exhaustive list of companies profiled in the report.

In September 2020, Sun Pharma announced the launch of the monoclonal antibody-ILUMYA in Japan.